Related Experiment Videos
Alpha-interferon in childhood: a review
A Baruchel1, T Leblanc, G Schaison
1Unité d'Hématologie Pédiatrique, Hôpital Saint-Louis, Paris, France.
Nouvelle Revue Francaise D'Hematologie
|January 1, 1994
Summary
Alpha-interferon (alpha-IFN) shows promise for pediatric conditions like hepatitis and ITP. More research is required to confirm its effectiveness in myeloproliferative diseases, acute leukemias, and hemangiomas.
Area of Science:
- Pediatric Hematology and Oncology
- Immunology
- Hepatology
Background:
- Alpha-interferon (alpha-IFN) is an immunomodulatory cytokine with established therapeutic roles.
- Its application in pediatric populations requires specific evaluation due to developmental differences.
Purpose of the Study:
- To review current and potential pediatric indications for alpha-interferon therapy.
- To identify areas where further clinical investigation is warranted.
Main Methods:
- Comprehensive literature review of studies involving alpha-interferon in pediatric patients.
- Analysis of existing data on efficacy and safety across various conditions.
Main Results:
- Alpha-interferon has demonstrated potential in certain pediatric conditions.
- Evidence suggests a need for further prospective studies in specific hematologic and oncologic indications.
Conclusions:
- Further prospective studies are essential to establish the role of alpha-interferon in pediatric myeloproliferative diseases, acute leukemias, chronic hepatitis, severe hemangiomas, and chronic idiopathic thrombocytopenic purpura (ITP).
- Definitive treatment guidelines for these pediatric conditions require additional clinical validation.